

CONSOLIDATED TURNOVER

31 DECEMBER 2007

CEGEDIM HAS WHAT IT TAKES TO MEET ITS AMBITIONS

Paris, 12 February 2008 - CEGEDIM, the world leader in CRM solutions for the pharmaceutical industry, increased its full-year turnover to over €750 million due notably to a particularly strong fourth quarter. This momentum is proof that US-based Dendrite has been successfully integrated into CEGEDIM's core "CRM and strategic data" business.

Turnover in thousands of euros (*)	2007	2006	Variation	Organic growth %
CRM and strategic data	436,212	244,612	78.3%	(**) 78.2%
Healthcare professionals	147,186	125,640	17.1%	10.6%
Healthcare insurance services	81,120	77,265	5.0%	5.8%
Healthcare and strategic data: A	664,518	447,517	48.5%	46.8%
Technologies and services: B	91,535	93,692	-2.3%	13.4%
Total: A + B	756,053	541,209	39.7%	41.6%
First quarter	136,050	126,250	7.8%	5.8%
Second quarter	197,090	139,518	41.3%	40.2%
Third quarter	191,707	120,721	58.8%	64.8%
Fourth quarter	231,206	154,720	49.4%	55.7%
Total	756,053	541,209	39.7%	41.6%

(*) *Businesses sold to Tessi on 3 July 2007 are consolidated over 6 months in 2007 turnover and over 12 months in 2006 turnover, but are restated on a 6-month basis for calculating growth from continuing operations.*

(**) *Including, from 9 May 2007, the activities of Dendrite, whose impact is no longer distinguishable from "CRM and strategic data" activities because of intervening mergers.*

CEGEDIM Group now generates over 50% of its business abroad.

15% of the consolidated turnover is made in US dollars and would have generated additional turnover of around 5 million euros, on a constant dollar basis over 2007.

International businesses of "CRM and strategic data" activities, a sector dedicated to the pharmaceutical industry, rose from 55% of the total in 2006 to 73% in 2007. Business in this sector is still growing briskly in Europe and has posted some nice successes in Asia. Moreover, Cegedim Dendrite is now a major player in the Americas.

“**Healthcare professionals**” activities confirmed their impressive growth trend, with fourth-quarter gains that outpaced those of the third quarter. Generating growth of over 17% in 2007, CEGEDIM is consolidating its position in the market for healthcare professionals’ software.

The “**Healthcare insurance services**” sector also confirmed its positive trends.

Cegelease’s momentum still accounts for much of the strong growth at the “**Technologies and services**” division.

Outlook

We are still right on target for a FY 2007 operating margin of 13%, excluding the businesses sold to Tessi on 3 July 2007 and the restructuring costs related to the 9 May 2007 Dendrite acquisition.

About CEGEDIM:

Founded in 1969, CEGEDIM supplies services, technological tools, databases and data flow management services. CEGEDIM’s expertise falls into two divisions. The “Healthcare and strategic data” division comprises services specifically designed for pharmaceutical companies, healthcare professionals and health insurance providers. The “Technologies and services” division covers a variety of sectors.

Established as the world leader in Pharmaceutical CRM, its historic core business, CEGEDIM employs nearly 8,000 people in 80 countries. CEGEDIM generated turnover of €756 million in 2007.

To learn more, please see our website: www.cegedim.com

Listed on Euronext Paris, compartment B – ISIN FR0000053506 – Reuters CGDM.PA – Bloomberg CGM

Media inquiries

CEGEDIM

Aude Balleydier
Media Relations
Tel: + 33 (0)1 49 09 68 81
aude.balleydier@cegedim.fr

VP COMMUNICATION

Coralie Voigt
Press Officer
Tel: + 33 (0)1 40 22 04 01
cvoigt@vp-communication.com

Investor relations

CEGEDIM

Sandrine Debroise
Chief Financial Officer

Annelise Falandry
Project Supervisor

Antoine Alazard
Project leader

Tel: + 33 (0)1 49 09 22 00
investor.relations@cegedim.fr